News
The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Partners. The readout also represents the second late-stage win for the Merck and Kelun-Biotech asset, called sac-TMT.
FEATURED STORIES
After a sluggish 2025, biotech IPOs have roared back to life. Fueled by resilient stock performances and improving market sentiment, the total number of public debuts so far this year has already eclipsed 2025’s total.
Biopharma is entering its second-quarter earnings season riding high on a wave of massive deals and venture capital flow, plus a clearing of regulatory and policy overhangs. What can industry watchers expect to hear on the upcoming investor calls?
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.
In spite of a tumultuous economy, many life science companies have started the year off strong. With plans to expand its team and pipeline in the coming year, Takeda is one of them.
Job hopping– frequently changing jobs, typically within a short period of time – gained popularity with the onset of COVID-19 and is still popular now. Here’s what recruiters think about job hopping.
Bellicum Pharmaceuticals has ended the only clinical trials evaluating its GoCAR-T cell product in combination with rimiducid following serious safety concerns.
Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.
Jounce Therapeutics has received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce’s equity at a per-share price of $1.80 in cash.
Weeks after the FDA rejected Veru’s Emergency Use Authorization bid for sabizabulin in COVID-19, the company announced plans to continue with late-stage development of the drug.
CytoDyn has spent the past two years under siege. In an exclusive interview, Cyrus Arman, president, told BioSpace how the company is looking to turn the page.
The life sciences industry saw modest salary growth compared to recent years and gaps persisted for women and racial and ethnic minorities.
To hone in on its growth areas, Novartis is looking to trim its ophthalmology portfolio and sell off some of its assets, according to a Bloomberg report published Tuesday.